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with hepatocellular carcinoma (HCC) that had progressed following ﬁrst-line sorafenib.
Patients and methods: Thirty-six patients with Barcelona Clinic Liver Cancer stage B or C
HCC and preserved to mildly impaired liver function (Child–Pugh class A) received regorafe-
nib 160 mg once daily in cycles of 3 weeks on/1 week off treatment until disease progression,
unacceptable toxicity, death or patient/physician decision to discontinue. The primary end-
point was safety; secondary end-points included efﬁcacy (including time to progression and
overall survival).
Results: The median treatment duration was 19.5 weeks (range 2–103). At data cutoff, three
patients remained on treatment. Reasons for discontinuation were adverse events (n = 20),ed by Elsevier Ltd.
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J. Bruix et al. / European Journal of Cancer 49 (2013) 3412–3419 3413disease progression (n = 10), consent withdrawal (n = 2) and death (n = 1). Seventeen patients
required dose reductions (mostly for adverse events [n = 15]); 35 patients had treatment inter-
ruption (mostly for adverse events [n = 32] or patient error [n = 11]). The most frequent treat-
ment-related adverse events were hand–foot skin reaction (any grade n = 19; gradeP3 n = 5),
diarrhoea (n = 19; n = 2), fatigue (n = 19; n = 6), hypothyroidism (n = 15; n = 0), anorexia
(n = 13; n = 0), hypertension (n = 13; n = 1), nausea (n = 12; n = 0) and voice changes
(n = 10; n = 0). Disease control was achieved in 26 patients (partial response n = 1; stable dis-
ease n = 25). Median time to progression was 4.3 months. Median overall survival was
13.8 months.
Conclusion: Regorafenib had acceptable tolerability and evidence of antitumour activity in
patients with intermediate or advanced HCC that progressed following ﬁrst-line sorafenib.
 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Improved understanding of the molecular pathogen-
esis of hepatocellular carcinoma (HCC) has highlighted
the role of several angiogenic and oncogenic signalling
pathways, which oﬀer promising targets for therapy.1,2
In clinical trials, the tyrosine kinase inhibitor (TKI)
sorafenib, which targets vascular endothelial growth fac-
tor receptor (VEGFR), platelet-derived growth factor
receptor (PDGFR) and Raf, was associated with signif-
icantly longer time to progression and improved overall
survival compared with placebo.3,4 As a result, sorafenib
has become the standard of care as ﬁrst-line systemic
therapy for patients with advanced HCC.5,6
Unfortunately, the beneﬁts of sorafenib may not be
sustained (median time to radiological progression
2.8–5.5 months in the phase III clinical trials3,4),
although patients with good liver function could well
beneﬁt from further therapy.7 To date, no available
agents have shown clinical beneﬁt as second-line treat-
ment following sorafenib, and the results of clinical tri-
als of several targeted therapies have been
disappointing. A phase III study of linifanib was halted
early for failing to meet the primary end-point,8 and
brivanib has failed in phase III trials in the ﬁrst-line9
and second-line10 settings (versus sorafenib and placebo,
respectively). Similarly, a non-inferiority phase III trial
comparing ﬁrst-line sunitinib with sorafenib failed,11
and concerns were raised about potential liver toxici-
ties.6,12 There is thus a pressing need for eﬀective and
tolerable options to allow patients with advanced
HCC to continue treatment after their disease progresses
on sorafenib.
We report here data from an uncontrolled, open-
label, phase II study of regorafenib as second-line ther-
apy in patients with HCC. Regorafenib is a novel mult-
ikinase inhibitor that targets kinases involved in
angiogenesis (e.g. VEGFR1–3 and TIE2), oncogenesis
(e.g. c-kit, Ret and wild-type and V600-mutated BRAF)
and the tumour microenvironment (e.g. PDGFR and
ﬁbroblast growth factor receptor).13 In preclinical
in vivo models, regorafenib showed a broad spectrum
of antitumour activity,13 and it has been evaluated asmonotherapy in clinical phase I14,15 to phase III trials
in patients with solid tumours, including colorectal can-
cer, renal cell cancer and HCC.16,17 A phase I study
identiﬁed a regorafenib dosing schedule of 160 mg once
daily in repeating cycles of 3 weeks on treatment fol-
lowed by 1 week oﬀ treatment as the recommended reg-
imen for further clinical investigation.14 We therefore
undertook the present study to assess the safety, eﬃcacy
and pharmacokinetics of regorafenib in the recom-
mended regimen in patients with HCC that had pro-
gressed following sorafenib treatment.
2. Patients and methods
The trial was conducted at 13 centres in Europe and
Asia. Each centre’s institutional review board or inde-
pendent ethics committee approved the protocol and
all patients provided written informed consent before
participation. The trial was conducted under the princi-
ples of the Declaration of Helsinki and its amendments,
in line with Good Clinical Practice and local laws and
regulations.
2.1. Patients
The study involved patients with Barcelona Clinic
Liver Cancer stage B or C5 HCC that would not beneﬁt
from treatments of established eﬃcacy, such as resec-
tion, liver transplantation, local ablation, chemoembol-
isation or sorafenib therapy. Eligibility criteria included
radiological progression following previous sorafenib
therapy with evidence of at least one new lesion; age
18 years or older; life expectancy of at least 3 months;
Eastern Cooperative Oncology Group performance sta-
tus 0 or 1; preserved to mildly impaired liver function
(non-cirrhotic or Child–Pugh class A); adequate bone-
marrow and renal function.
Exclusion criteria included the following: previous
systemic treatment with molecular targeted agents other
than sorafenib (including regorafenib); discontinuation
of previous sorafenib due to drug toxicity; bleeding risk
(e.g. major surgery, traumatic injury or clinically signif-
icant bleeding in the past month, thromboembolic event
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wound or ulcer); a history of cardiac disease or conges-
tive heart failure; uncontrolled hypertension; and other
primary cancers or central nervous system metastases.
2.2. Study medication
Participants received regorafenib 160 mg orally once
daily for the ﬁrst 3 weeks of each 4-week cycle, followed
by 1 week oﬀ treatment. Prespeciﬁed dose reductions (to
120 or 80 mg) and delay of the following cycle (up to
28 days) were allowed to manage adverse events. The dose
could be re-escalated to 160 mg at the investigator’s discre-
tion if the toxicity had resolved to baseline level. If the
patient required more than two dose reductions or a delay
of more than 28 days between cycles, regorafenib treatment
had to be stopped. Other reasons for treatment discontinu-
ation included clinical progression, intolerable toxicity,
withdrawal of consent and investigator decision that stop-
ping treatment would be in the patient’s best interest.
2.3. Assessments
The primary end-point of the study was to assess the
safety of regorafenib in patients with HCC that had pro-
gressed on treatment with sorafenib. Secondary end-
points included eﬃcacy and pharmacokinetics.
All patients who received at least one dose of rego-
rafenib and had one safety assessment after the start
of study medication were included in the safety analysis.
Safety variables included adverse events, laboratory
changes (haematology, clinical chemistry and urine
analysis), changes in vital signs (blood pressure, heart
rate, respiratory rate and temperature) and changes in
Child–Pugh class and electrocardiography. Patients
were assessed within 7 days before study start (within
14 days for physical examination and blood pressure
measurements), on days 1 and 15 of each cycle and
within 14 days after the end of treatment.
All treated patients were included in the eﬃcacy anal-
ysis. Eﬃcacy variables were time to progression (evalu-
ated using the modiﬁed version of the Response
Evaluation Criteria In Solid Tumors 1.0 [mRECIST]
proposed by Llovet et al. for use in HCC clinical tri-
als18,19), objective tumour response rate (com-
plete + partial response), disease control rate
(complete + partial response + stable disease) and over-
all survival. Tumour measurements were conducted
using computed tomography or magnetic resonance
imaging every 6 weeks (±7 days) for the ﬁrst six cycles
and then every three cycles (±14 days).
Blood samples for pharmacokinetic assessment were
collected after at least 14 days of uninterrupted stable
dosing of regorafenib in cycle 1 (or later cycle if
required) and at the start of the next treatment cycle.
Concentrations of regorafenib and its active metabolites
M2 (N-oxide metabolite; BAY 75-7495) and M5(N-oxide/N-desmethyl metabolite; BAY 81-8752) were
determined using a validated bioanalytical analysis.
2.4. Sample size calculation and statistical analysis
To achieve the primary objective (safety), a sample
size of approximately 31–38 patients (25–30 from Eur-
ope and 6–8 from Asia) was considered suﬃcient. This
was a single-arm, non-comparative study and data are
presented as descriptive summaries. Adverse events
and laboratory abnormalities are summarised by cate-
gory and grade using the National Cancer Institute
Common Terminology Criteria for Adverse Events ver-
sion 3.0. For eﬃcacy data, frequency counts and per-
centages are provided for response and disease control
rates; for analyses of time to progression and overall
survival, the median time to event and 95% conﬁdence
intervals (CIs) are calculated using the Kaplan–Meier
method. Peak and trough concentrations of regorafenib
and its metabolites are reported as geometric means with
coeﬃcient of variance (CV).
3. Results
Fifty-six patients signed the informed consent form;
however, 20 patients did not receive any study medica-
tion (screening failure n = 17, adverse event n = 1, death
n = 1 and consent withdrawal n = 1). Thus, from Sep-
tember 2009, 36 patients received at least one dose of
regorafenib and were included in the safety analysis.
Baseline characteristics of these 36 patients (median
age 61 years, range 40–76) are shown in Table 1. The
median duration of previous sorafenib treatment was
4.5 months (range 0.5–32.6).
3.1. Treatment duration
The median duration of regorafenib treatment was
19.5 weeks (range 2–103). At the data cutoﬀ (1st March
2012), three patients were still on treatment. In the
remaining 33 patients, the reasons for treatment discon-
tinuation were adverse events (n = 20, 56%), disease
progression (n = 10, 28%), withdrawal of consent
(n = 2, 6%) and death (n = 1, 3%).
Thirty-ﬁve patients (97%) required dose modiﬁca-
tions during the study: 17 patients (47%) required rego-
rafenib dose reduction, mostly to manage adverse events
(n = 15); 35 patients (97%) had at least one dose inter-
ruption during daily treatment or delay to the start of
the next cycle, mostly for adverse events (n = 32) or
patient error (n = 11); patients may have had dose mod-
iﬁcations for more than one reason.
3.2. Safety and tolerability
All 36 patients experienced at least one treatment-
emergent adverse event, and 35 of the 36 patients
Table 1
Baseline patient and tumour characteristics.
Regorafenib 160 mg
(n = 36)
n (%)
Sex Male 32 (89)
Female 4 (11)
Ethnicity Caucasian 26 (72)
Asian 10 (28)
Eastern Cooperative Oncology Group performance status 0 28 (78)
1 8 (22)
Barcelona Clinic Liver Cancer stage B (intermediate) 4 (11)
C (advanced) 32 (89)
Overall Child–Pugh score 5 27 (75)
6 9 (25)
Hepatitis infection B 14 (39)
C 13 (36)
Alcohol use Abstinent 28 (78)
Light 6 (17)
Moderate 2 (6)
Ascites Absent 35 (97)
Slight 1 (3)
Liver cirrhosis No 12 (33)
Yes 24 (67)
Number of target lesions 1 6 (17)
2 5 (14)
3 6 (17)
4 4 (11)
5 6 (17)
6 5 (14)
9 2 (6)
10 2 (6)
Tumour stage II 1 (3)
IIIA 6 (17)
IIIB 1 (3)
IIIC 1 (3)
IV 26 (72)
Unknown 1 (3)
Number of previous lines of chemotherapy (any intention)a 1 30 (83)
2 4 (11)
3 1 (3)
4 1 (3)
a Previous chemotherapy agents included sorafenib (n = 36; one patient received concomitant S-1; one patient received two lines of sorafenib
[ﬁrst- and third-line treatment]), capecitabine monotherapy (n = 1), capecitabine + cisplatin (n = 1), capecitabine + thalidomide (n = 1), doxoru-
bicin monotherapy (n = 1), doxorubicin + cisplatin (n = 1), gemcitabine + cisplatin (n = 1), mitoxantrone (n = 1), not speciﬁed (n = 1).
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Twenty-one patients (58%) had a grade 3 or higher
drug-related adverse event. The most frequent drug-
related, treatment-emergent adverse events are shown
in Table 2.
Five patients (14%) experienced serious adverse
events that were deemed to be related to the study med-
ication: these events were grade 2 fever (n = 1; regorafe-
nib treatment interrupted), grade 3 diarrhoea (n = 1;
regorafenib treatment permanently stopped), grade 3
supraventricular arrhythmia/atrial ﬁbrillation (n = 1;regorafenib treatment permanently stopped), grade 4
fatigue (n = 1; regorafenib treatment interrupted) and
grade 5 haematoma in the right thigh following a fall
(n = 1; patient died 44 days after starting regorafenib
treatment). Seven other patients died as a result of
adverse events during the study or survival follow up;
none of these deaths was deemed to be related to study
medication. Details of these deaths are as follows. Two
patients died from liver failure: one patient had previ-
ously experienced rapid progression of HCC from stage
II to stage IV in 9 months despite sorafenib treatment,
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on regorafenib, stopped treatment 2 weeks later and
died 16 days after the last dose; the other patient had
evidence of grade 3 aspartate aminotransferase and
grade 2 alanine aminotransferase at baseline and died
from hepatic encephalopathy 23 days after stopping
regorafenib treatment, which he had received for
9 weeks. Two patients experienced central nervous sys-
tem haemorrhage 2 and 5 months, respectively, after
starting regorafenib treatment: one patient, with mild
coagulopathy and thrombocytopenia at baseline, suf-
fered a high-impact accidental head injury with a basal
skull fracture, subdural haematoma and high intracra-
nial pressures—the patient did not recover and died
postoperatively; the other had progression of HCC at
multiple sites and normal coagulation parameters, but
experienced bleeding into a new cerebral metastasis
and died several months after treatment discontinua-
tion. One patient died from an unspeciﬁed metabolic
or laboratory disorder 10 months after starting regorafe-
nib. Two patients had other adverse events deemed to be
due to disease progression, both of which occurred dur-
ing survival follow up (at 6.6 and 13.8 months after
starting regorafenib treatment) and were reported with-
out details of the speciﬁc adverse event or relationship to
treatment.
Among the 18 patients (50%) who stopped study
medication as a result of adverse events, the reason
was deemed to be related to study medication in seven
patients (19%), including fatigue in four patients (inTable 2
Drug-related, treatment-emergent adverse events aﬀecting at least 10%
of patients at any grade, or at least 5% of patients at grade 3 or higher.
Any grade Grade P3
n (%) n (%)
Any adverse event 35 (97) 21 (58)
Diarrhoea 19 (53) 2 (6)
Fatigue 19 (53) 6 (17)
Hand–foot skin reaction 19 (53) 5 (14)
Hypothyroidism 15 (42) 0
Anorexia 13 (36) 0
Hypertension 13 (36) 1 (3)
Nausea 12 (33) 0
Voice changes 10 (28) 0
Constipation 9 (25) 0
Headache 7 (19) 0
Weight loss 7 (19) 0
Proteinuria 6 (17) 1 (3)
Oral mucositis 5 (14) 1 (3)
Vomiting 5 (14) 0
Abdominal pain 4 (11) 1 (3)
Anaemia 4 (11) 1 (3)
Fever 4 (11) 0
Hyperbilirubinaemia 4 (11) 2 (6)
Hyperthyroidism 4 (11) 1 (3)
Mood alteration, depression 4 (11) 0
Hypophosphataemia 2 (6) 2 (6)association with dysphagia and hand–foot skin reaction
in one patient and with an unspeciﬁed dermatological
condition, anorexia and proteinuria in another) and
three patients with the serious adverse events described
above: haematoma, supraventricular arrhythmia/atrial
ﬁbrillation and diarrhoea.
All 36 patients had abnormal laboratory results dur-
ing the study. The most frequent laboratory abnormali-
ties were raised aspartate aminotransferase (n = 33,
92%), anaemia (n = 31, 86%), raised alkaline phospha-
tase (n = 30, 83%) and raised gamma glutamyltransfer-
ase (n = 30, 83%). The most frequent grade 3
laboratory abnormalities were raised gamma glutamyl-
transferase (n = 13, 36%), hypophosphataemia (n = 10,
28%), hyponatraemia (n = 9, 25%), lymphopenia
(n = 6, 17%), hyperbilirubinaemia (n = 5, 14%) and
raised aspartate aminotransferase (n = 4, 11%). For
most patients, there was no change from baseline in
worst grade of haematological and biochemical
toxicities.
Laboratory test abnormalities were reported as
adverse events in any of the following situations: they
caused the patient to withdraw from the study, they
required treatment, they caused apparent clinical mani-
festations, or they were judged to be clinically relevant
by an investigator. Drug-related biochemistry labora-
tory adverse events of any grade were reported in 14
regorafenib-treated patients (39%), and were usually
mild in severity, with grade 3 laboratory adverse events
reported in four patients (11%). The most frequent rego-
rafenib-related laboratory adverse events were protein-
uria (n = 4, 11%), acidosis (n = 3, 8%), bilirubin
(n = 3, 8%), creatinine (n = 2, 6%), hypoalbuminaemia
(n = 2, 8%) and hypophosphataemia (n = 2, 6%).3.3. Eﬃcacy
The median time to progression was 4.3 months (95%
CI 2.9–13.1; Fig. 1). The progression-free rate was 65%
(95% CI 45–79%) at 3 months and 44% (95% CI 26–
60%) at 6 months. Median overall survival was
13.8 months (95% CI 9.3–18.3; Fig. 2). The overall sur-
vival rate was 88% (95% CI 72–95%) at 3 months and
79% (95% CI 61–89%) at 6 months.
Fig. 3 shows the best change in target lesion from
baseline in 31 evaluable patients. The best response,
based on mRECIST, was partial response in one patient
(3%), stable disease in 25 patients (69%) and progressive
disease in ﬁve patients (14%). Response was not assess-
able in ﬁve patients (14%). As a result, the overall
response rate (complete + partial response) for regorafe-
nib was 3% and the disease control rate (com-
plete + partial response + stable disease) was 72%. In
the patient with partial response, the time to response
was 1.3 months, the duration of response was
Su
rv
iv
al
 d
is
tri
bu
tio
n 
fu
nc
tio
n
0
Time from first treatment (months)
1.00
0.75
0.50
0.25
0.00
3 6 9 12 15 18 21
Censored observations
Fig. 1. Time from start of treatment to disease progression, measured
using modiﬁed Response Evaluation Criteria In Solid Tumors 1.0.19,20
Median time to progression was 4.3 months (95% conﬁdence interval
2.9–13.1).
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Fig. 2. Kaplan–Meier estimate of overall survival from start of
treatment to data cutoﬀ date of 1st March 2012. Median overall
survival was 13.8 months (95% conﬁdence interval 9.3–18.3).
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was 33%.3.4. Pharmacokinetics
The mean maximum plasma concentration of rego-
rafenib in Caucasian patients was 1772.1 lg/l (CV
94.86; n = 20) at steady state on day 15; the mean trough
concentration was 50.9 lg/l (CV 260.19; n = 14) on day
1 of the following cycle after 7 days oﬀ treatment. The
equivalent mean concentrations for the M2 and M5
metabolites were 1112.3 lg/l (CV 155.93) and
858.8 lg/l (CV 144.66), respectively, at steady state on
day 15 and 25.7 lg/l (CV 393.46) and 277.2 lg/l (CV
447.44), respectively, after 7 days oﬀ treatment. For
Asian patients (n = 8), the mean maximum concentra-
tions of regorafenib, M2 and M5 on day 15 of cycle 1
were 2509.3 lg/l (CV 40.96), 862.2 lg/l (CV 76.17) and
336.2 lg/l (CV 150.43), respectively. Additional phar-
macokinetic data from Asian patients are provided
online as Supplementary Material.4. Discussion
The present study is the ﬁrst to investigate the safety
and antitumour activity of regorafenib in patients with
HCC progressing after ﬁrst-line sorafenib treatment,
using a dose schedule of 160 mg once daily in repeating
4-week cycles of 3 weeks on, 1 week oﬀ treatment.
Although all patients experienced at least one adverse
event during treatment, these could typically be man-
aged with supportive measures and dose reductions or
treatment interruption, and relatively few patients
needed to stop treatment permanently because of
drug-related adverse events (n = 7, 19%). Drug-related
laboratory adverse events occurred in 14 patients
(39%), and were mostly mild in severity. Only ﬁvepatients (14%) experienced drug-related serious adverse
events, and only one death during the study was deemed
to be related to study medication (haematoma in the
right thigh following a fall).
It is noteworthy that our patients had tolerated prior
treatment with sorafenib. The toxicity proﬁles of these
two kinase inhibitor agents are somewhat similar, with
diarrhoea, fatigue and hand–foot skin reaction being
the most frequently reported adverse events in the
SHARP and Asia-Paciﬁc trials of sorafenib, as well as
in our trial and other studies of regorafenib in patients
with diﬀerent tumour types.3,4,14–17,20,21
In patients with HCC, liver failure is a major concern
and severe drug-related liver toxicities have been
reported in trials of other TKIs in HCC (e.g. suniti-
nib6,12). In our study, two patients died from liver dys-
function, but neither case was deemed to be related to
study medication. Furthermore, liver function tests
showed no sudden signiﬁcant increases in liver transam-
inases that might indicate acute liver damage leading to
progressive liver failure. In fact, more than half of the
patients maintained Child–Pugh status A throughout
the study (data not shown), and most patients had no
change from baseline in grade of biochemical and hae-
matological toxicities.
Eﬃcacy data from this study indicate promising anti-
tumour activity of regorafenib in patients with progres-
sive HCC following sorafenib treatment. Over a median
treatment duration of 19.5 weeks, nearly three-quarters
of patients (n = 26, 72%) achieved disease control, with
a median time to progression of 4.3 months and median
overall survival of 13.8 months. We chose time to pro-
gression as an end-point, rather than progression-free
survival, to avoid the risk of counting death from under-
lying liver disease as progression.18 Furthermore, pro-
gression-free survival has been criticised as an end-
point in HCC phase III clinical trials because there is
no evidence that it translates into meaningful beneﬁt
for patients in terms of overall survival or quality of
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3418 J. Bruix et al. / European Journal of Cancer 49 (2013) 3412–3419life.5,22,23 Time to progression is also preferred as an
end-point over tumour response because targeted ther-
apy typically has a cytostatic rather than a cytotoxic
eﬀect, and may therefore not have a visible eﬀect on
tumour size.18 Indeed, sorafenib had no signiﬁcant
impact on tumour response in the pivotal SHARP trial,
although survival end-points were clearly improved ver-
sus placebo.3 While time to progression still needs to be
validated as a meaningful and relevant surrogate marker
of overall survival, an international panel of experts has
recommended that it should be included as a primary
eﬃcacy end-point in all future phase II trials of treat-
ments for advanced HCC.18
We believe that our study shows promise for rego-
rafenib in the second-line treatment of patients with pro-
gressive HCC, in terms of a manageable adverse event
proﬁle and evidence of antitumour activity, which war-
rant further investigation in a phase III trial (recently
opened to recruitment, ClinicalTrials.gov identiﬁer
NCT01774344). Nonetheless, we acknowledge that our
study has limitations: robust data to allow baseline
assumptions for time to progression in second-line ther-
apy are not available and second-line trials may have a
risk of selection bias, as participants are likely to have
underlying liver disease. However, the treated natural
history of HCC has been changing since the pivotal
sorafenib trials, and patients are often started on ﬁrst-
line sorafenib at an earlier disease stage than in the
phase III studies; this is having an impact on overall sur-
vival in both ﬁrst- and, potentially, second-line settings.
Further studies are needed to explore how the impact of
ﬁrst-line treatment on survival is likely to aﬀect
outcomes in second-line therapy.The present study suggests that, in patients with
advanced HCC that has progressed following ﬁrst-line
treatment with sorafenib, regorafenib can be beneﬁcial.
The mechanism by which regorafenib may overcome
resistance to sorafenib remains to be investigated in
future studies.
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